# BennuBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bennubio

- Industry: Biotechnology
- Headquarters: Albuquerque, US
- Website: www.bennubio.com
- Total disclosed funding: $6.5M
- Latest round: Series B (Mar 25, 2020)
- Investors on record: 5

## About

BennuBio, Inc. is a biotechnology firm specializing in innovative flow cytometry systems, aimed at enhancing biological research through advanced analysis of multicellular models.Founded in 2018 and headquartered in Albuquerque, US, BennuBio, Inc. develops advanced flow cytometry technologies. The company has successfully completed two deals, with its most recent funding round being a Series B on March 25, 2020, led by Co-Win Ventures. The CEO is John Orourke, with Steven Graves as a founder.BennuBio, Inc. specializes in advanced flow cytometry equipment, with its flagship product being the Velocyt®, designed for the analysis of 3D multicellular model systems. This technology facilitates high-throughput analysis, processing sample volumes up to 100 times faster than traditional methods. The Velocyt® accommodates a wide range of samples, from microliters to milliliters, including single cells and complex 3D structures, while preserving undiluted samples for further analysis. Key applications include intact spheroid and organoid analysis, C. elegans analysis, and bioprocessing, serving research institutions, biotechnology firms, and pharmaceutical companies primarily in the US and expanding internationally into Europe and Asia.BennuBio generates revenue through direct sales of its Velocyt® flow cytometry systems and related services, focusing on business-to-business transactions with research institutions and commercial research entities. Transactions are structured around individual product sales, with opportunities for ongoing service agreements for maintenance and support. Given the advanced nature of its equipment, pricing is tailored to reflect the sophistication of the technology, with revenue derived from both initial purchase agreements and recurring service contracts, supported by partnerships in the scientific community to enhance market penetration.BennuBio plans to utilize its recent Series B funding raised in March 2020 to support the development of new products and expand into international markets. Specific regions targeted for expansion include Europe and Asia, aiming for entry by 2022. The company is focused on enhancing its Velocyt® platform capabilities, which are expected to contribute to future growth and increased market share in advanced analytical tools for biological research.

## Funding rounds

- Series B, Mar 25, 2020, $5M — Sun Mountain Capital, Cottonwood Technology Fund, Co-Win Ventures, Tramway Venture Partners
- Series A, Aug 31, 2018, $1.5M — Sun Mountain Capital, Cottonwood Technology Fund, Catalyst Fund, Tramway Venture Partners

## Investors

- Sun Mountain Capital (https://capitalatlas.ai/funds/sun-mountain-capital) — Series A, Series B
- Cottonwood Technology Fund (https://capitalatlas.ai/funds/cottonwood-technology-fund) — Series A, Series B
- Catalyst Fund (https://capitalatlas.ai/funds/catalyst-fund) — Series A
- Tramway Venture Partners (https://capitalatlas.ai/funds/tramway-venture-partners) — Series A, Series B
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series B